COMPASS STUDY PRESENTED AT ESC CONGRESS 2017 – LARGEST RIVAROXABAN STUDY TO DATE, ENROLLED 27,395 PATIENTS TO INVESTIGATE CAD AND PAD Bayer’s data shows Xarelto® (rivaroxaban) significantly lowers the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results